|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
BEFREE |
Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.
|
30348199 |
2018 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
ONO-8430506 also decreased plasma TNF-α and G-CSF cytokine levels by >70% and leukocyte infiltration in breast tumors and adjacent adipose tissue by >50%.
|
26071407 |
2015 |
|
Mammary Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
|
17047649 |
2006 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
|
17047649 |
2006 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Mammary Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
|
16076697 |
2005 |
|
Mammary Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
|
16076697 |
2005 |
|
Mammary Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
|
12926135 |
2003 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
|
12926135 |
2003 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression.
|
9018096 |
1996 |
|
Mammary Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression.
|
9018096 |
1996 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
|
7543699 |
1995 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Astemizole in the treatment of granulocyte colony-stimulating factor-induced bone pain.
|
7541186 |
1995 |
|
Mammary Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
Astemizole in the treatment of granulocyte colony-stimulating factor-induced bone pain.
|
7541186 |
1995 |
|
Mammary Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
|
7543699 |
1995 |
|
Mammary Neoplasms
|
0.320 |
Therapeutic
|
group |
CTD_human |
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
|
7692001 |
1993 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
|
7692001 |
1993 |